Company: IMNN
Filing Date: 2025-06-13
Form Type: 424B3
Source: 0001641172-25-015119
Chunk: 4

Company: Imunon, Inc.
Filing Date: 2025-06-13
Form: 424B3
Chunk 4
---
 to you in making an investment decision. This summary is qualified in its entirety by the more detailed information included in or incorporated by reference into this prospectus. Before making your investment decision with respect to our securities, you should carefully read the entire prospectus, including the risks of investing in our securities discussed under the heading “Risk Factors” and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part.

Business Overview

Imunon is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms with the aim to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases.

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase II clinical trial (OVATION 2). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnerships, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions.

Private Placement

On May 23, 2025, the Company entered into a securities purchase agreement (the “ Purchase Agreement”) with certain institutional and accredited investors for the issuance and sale in the Private Placement of (i) 2,777,779 shares of Common Stock, (ii) Pre-Funded Warrants to purchase up to 4,444,444 shares of Common Stock, at an exercise price of $0.0001 per share,